Javascript must be enabled to continue!
Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index
View through CrossRef
Abstract
Objective
BILAG-2004 index is a comprehensive disease activity instrument for SLE but administrative burden and frequency of errors limits its use in routine practice. We aimed to develop a tool for more accurate, time-efficient scoring of BILAG-2004 index with full fidelity to the existing instrument.
Methods
Frequency of BILAG-2004 items was collated from a BILAG-biologics registry (BILAG-BR) dataset. Easy-BILAG prototypes were drafted to address known issues affecting speed and accuracy. After expert-verification, accuracy and usability of the finalised Easy-BILAG was validated against standard format BILAG-2004 index in a workbook exercise of 10 case vignettes. 33 professionals with a range of expertise from 14 UK centres completed the validation exercise.
Results
Easy-BILAG incorporates all items present in ≥5% BILAG-BR records, plus full constitutional and renal domains into a rapid single-page assessment. An embedded glossary and colour-coding assists scoring each domain. A second page captures rarer manifestations when needed. In the validation exercise, Easy-BILAG yielded higher median scoring accuracy (96.7%) than standard BILAG-2004 documentation (87.8%, p=0.001), with better inter-rater agreement. Easy-BILAG was completed faster (59.5min) than the standard format (80.0min, p=0.04) for 10 cases. An advantage in accuracy was observed with Easy-BILAG use among general hospital rheumatologists (91.3 vs 75.0, p=0.02), leading to equivalent accuracy as tertiary centre rheumatologists. Clinicians rated Easy-BILAG as intuitive, convenient, and well adapted for routine practice.
Conclusion
Easy-BILAG facilitates more rapid and accurate scoring of BILAG-2004 across all clinical settings which could improve patient care and biologics prescribing. Easy-BILAG should be adopted wherever BILAG-2004 assessment is required.
Title: Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index
Description:
Abstract
Objective
BILAG-2004 index is a comprehensive disease activity instrument for SLE but administrative burden and frequency of errors limits its use in routine practice.
We aimed to develop a tool for more accurate, time-efficient scoring of BILAG-2004 index with full fidelity to the existing instrument.
Methods
Frequency of BILAG-2004 items was collated from a BILAG-biologics registry (BILAG-BR) dataset.
Easy-BILAG prototypes were drafted to address known issues affecting speed and accuracy.
After expert-verification, accuracy and usability of the finalised Easy-BILAG was validated against standard format BILAG-2004 index in a workbook exercise of 10 case vignettes.
33 professionals with a range of expertise from 14 UK centres completed the validation exercise.
Results
Easy-BILAG incorporates all items present in ≥5% BILAG-BR records, plus full constitutional and renal domains into a rapid single-page assessment.
An embedded glossary and colour-coding assists scoring each domain.
A second page captures rarer manifestations when needed.
In the validation exercise, Easy-BILAG yielded higher median scoring accuracy (96.
7%) than standard BILAG-2004 documentation (87.
8%, p=0.
001), with better inter-rater agreement.
Easy-BILAG was completed faster (59.
5min) than the standard format (80.
0min, p=0.
04) for 10 cases.
An advantage in accuracy was observed with Easy-BILAG use among general hospital rheumatologists (91.
3 vs 75.
0, p=0.
02), leading to equivalent accuracy as tertiary centre rheumatologists.
Clinicians rated Easy-BILAG as intuitive, convenient, and well adapted for routine practice.
Conclusion
Easy-BILAG facilitates more rapid and accurate scoring of BILAG-2004 across all clinical settings which could improve patient care and biologics prescribing.
Easy-BILAG should be adopted wherever BILAG-2004 assessment is required.
Related Results
O19 Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004
O19 Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004
Abstract
Background/Aims
BILAG-2004 index is required to prescribe and monitor biologics in SLE. It is more comprehensive and responsive than the SLE...
Three in One: Systemic Lupus Erythematosus, HELLP Syndrome, and Antiphospholipid Syndrome: A Case Report and Literature Review
Three in One: Systemic Lupus Erythematosus, HELLP Syndrome, and Antiphospholipid Syndrome: A Case Report and Literature Review
Abstract
Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease commonly affecting women of reproductive age. Its overlap with HELLP syndrome (Hemolysi...
Precision medicine and patient perspectives in systemic lupus erythematosus
Precision medicine and patient perspectives in systemic lupus erythematosus
<p dir="ltr">Systemic lupus erythematosus (SLE) is an autoimmune disease (AID) with diverse clinical presentations and complex immunopathogenesis. Its chronic and variable co...
Precision medicine and patient perspectives in systemic lupus erythematosus
Precision medicine and patient perspectives in systemic lupus erythematosus
<p dir="ltr">Systemic lupus erythematosus (SLE) is an autoimmune disease (AID) with diverse clinical presentations and complex immunopathogenesis. Its chronic and variable co...
Pathogenesis of Autoimmunity/Systemic Lupus Erythematosus (SLE)
Pathogenesis of Autoimmunity/Systemic Lupus Erythematosus (SLE)
SLE is characterized by the generation of a variety of autoantibodies including anti-dsDNA autoantibodies, causing damage in various organs. If autoimmunity is defined by the gener...
P169 A validated two-score system for interferon is a predictor of response to rituximab in SLE
P169 A validated two-score system for interferon is a predictor of response to rituximab in SLE
Abstract
Background/Aims
We developed two interferon-stimulated gene (ISG) expression scores (IFN-Score-A and IFN-Score-B) that predict clinical outc...
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can present with a variety of clinical manifestations, ranging from mild skin involvement to multisystemic ...
Cross-sectional analysis of adverse outcomes in 1,029 pregnancies of Afro-Caribbean women in Trinidad with and without systemic lupus erythematosus
Cross-sectional analysis of adverse outcomes in 1,029 pregnancies of Afro-Caribbean women in Trinidad with and without systemic lupus erythematosus
AbstractThe objective of the study was to examine pregnancy outcomes in women with systemic lupus erythematosus (SLE) and population controls in Trinidad. We performed a cross-sect...

